Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis-Reference-Cited by-同舟云学术

Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis

Published:2017-10-10 Issue:11 Volume:10 Page:1177-1189
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Kayser Sabine¹²,Levis Mark J³,Schlenk Richard F⁴

Affiliation:

1. Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany

2. Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany

3. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA

4. National Center for Tumor Diseases, Heidelberg, Germany

Funder

National Cancer Institute

NCI

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2017.1387051

Reference106 articles.

1. Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C

2. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412

3. A quantitative analysis of kinase inhibitor selectivity

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023);Journal of Medicinal Chemistry;2024-07-12

2. Advancements and Challenges in the Treatment of AML;American Society of Clinical Oncology Educational Book;2024-06

3. Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice;Heliyon;2024-01

4. Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications;MedComm;2023-05-02

5. The clinical impact of the molecular landscape of acute myeloid leukemia;Haematologica;2023-02-01